Clinical Research Directory
Browse clinical research sites, groups, and studies.
Canagliflozin in Advanced Renal Disease With MRI Endpoints
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance dialysis. Our primary aim is to determine the effect of canagliflozin on cardiac structure and function in patients with advanced chronic kidney disease (CKD), compared with placebo. We hypothesize that canagliflozin will improve left ventricular (LV) hypertrophy in patients with advanced CKD. Our secondary aims are to describe the effect of canagliflozin on other cardiac magnetic resonance imaging parameters and surrogate markers of efficacy in this population.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
92
Start Date
2024-05-01
Completion Date
2029-03-30
Last Updated
2025-12-08
Healthy Volunteers
No
Conditions
Interventions
Canagliflozin 300Mg Tab
Patients will get 1 pill of Canagliflozin 300 mg daily for one year.
Placebo
Patients will get 1 pill of placebo daily for one year.
Locations (1)
McGill University Health Center
Montreal, Quebec, Canada